Discussion on current and future treatments for BCG-unresponsive HR NMIBC presented at ESMO 2023.
This is a video synopsis/summary of a panel discussion involving Sia Daneshmand, MD.
Daneshmand discusses treatment options for BCG-unresponsive non–muscle invasive bladder cancer. Though radical cystectomy cures most patients, it has high morbidity/mortality risks, especially in elderly patients. Alternatives are needed.
If a clinical trial is unavailable or unwanted, options include doublet chemotherapy with gemcitabine plus docetaxel chemotherapy or pembrolizumab immunotherapy. Retrospective data shows 50% 2-year recurrence-free survival with gemcitabine/docetaxel. Pembrolizumab has 25% to 40% response rates.
Valrubicin, the first FDA-approved drug in this setting, has a poor 10% to 15% 1-year recurrence-free survival. More recent options include nadofaragene firadenovec. the first intravesical gene therapy (once every 3 months) with 25% to 40% 1-year recurrence-free survival.
Daneshmand notes clinical trials remain the preferred option, but new FDA-approved treatments provide alternatives for BCG-unresponsive patients. He is excited about the increasing options for this patient population.
Video synopsis is AI-generated and reviewed by AJMCÒ editorial staff.
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen